Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
DNLI Stock Chart & Stats
$21.18
$0.28(1.32%)
At close: 4:00 PM EST
$21.18
$0.28(1.32%)
Day’s Range― - ―
52-Week Range$10.57 - $23.77
Previous CloseN/A
Volume399.31K
Average Volume (3M)1.66M
Market Cap
$3.36B
Enterprise Value$3.13B
Total Cash (Recent Filing)$867.88M
Total Debt (Recent Filing)$32.74M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
May 12, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding158,591,490
10 Day Avg. Volume1,553,114
30 Day Avg. Volume1,657,789
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio-6.86
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.09K
Enterprise Value/Ebitda-5.90
Forecast
1Y Price Target
$33.44Price Target Upside57.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.63
Revenue Forecast (FY)$61.12M
Bulls Say, Bears Say
Bulls Say
Delivery PlatformDenali's Transport Vehicle leveraging transferrin receptor shuttling enables delivery of therapies across the blood–brain barrier to neurons and muscle, increasing the potential to treat both central nervous system and peripheral manifestations of lysosomal diseases.
Efficacy BiomarkersTividenofusp alfa produced large, sustained reductions and normalization of cerebrospinal fluid and urine disease biomarkers along with decreases in neurofilament light, strengthening the case for accelerated approval and suggesting neuroprotective benefit.
Financing And Commercial PreparednessA substantial cash balance and external financing arrangements validate commercial potential, support launch readiness, and provide runway to advance multiple pipeline programs.
Bears Say
Clinical Hold And Preclinical SafetyA regulatory request for amended dosing and enhanced safety monitoring following preclinical hypersensitivity signals resulted in an investigational hold on an enzyme program, creating program‑specific delays and added development risk.
Regulatory RiskReliance on open‑label, single‑arm data combined with evolving agency expectations about surrogate endpoints increases the risk that confirmatory trials or regulatory scrutiny could delay or complicate approval decisions.
Safety Profile ConcernsInfusion‑related reactions are the most common adverse events observed in studies, presenting ongoing safety management needs that could affect patient acceptance, administration logistics, and product labeling.
Denali Therapeutics News
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $10.57 and its highest was $23.77 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $3.36B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 70 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.737 by $0.007.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.65.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 158,591,490 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.737. Following the earnings report the stock price went down -1.12%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Denali Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.44 (57.88% Upside)
$33.44 (57.88% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 965.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $864.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.87%
12-Months-Change
Fundamentals
Return on Equity
-45.69%
Trailing 12-Months
Asset Growth
-16.69%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
DNLI Stock 12 Month Forecast
Average Price Target
$33.44
▲(57.88% Upside)
Technical Analysis
Agios Pharma
―
Celcuity
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
6.75% Insiders
24.48% Mutual Funds
16.97% Other Institutional Investors
35.76% Public Companies and
Individual Investors